Learn more about oral JAK inhibitors for atopic dermatitis from dermatologist Dr. Ashley Sutherland
Eczema Society of Canada asked dermatologist Ashley Sutherland, MD, MSc, FRCPC, to share her expertise on the oral JAK inhibitor Rinvoq® (upadacitinib) and how this medication is used to manage atopic dermatitis (AD), the most common form of eczema.
What are oral JAK inhibitors?
For many patients with AD, their condition can be managed with prescription topical treatments and lifestyle measures. However, for some patients who live with uncontrolled moderate or severe AD, topical therapies may not be enough to control their disease, and their dermatologist may consider a systemic medication, such as an oral JAK inhibitor. An advanced therapy for AD can lead to clear skin and significant improvement in itch and skin rashes.
How does Rinvoq® work?
Oral Janus kinase (JAK) inhibitors treat AD by acting on overactive inflammatory pathways that lead to inflammation in AD, causing itch and rash.
Rinvoq® specifically targets JAK1, a key protein in pathways that fuel inflammation and itch in AD. Oral JAK inhibitors are used to calm overactive inflammatory pathways, which results in AD flares. Rinvoq® works to quickly improve itch and skin symptoms and bring relief to many patients.1
How is Rinvoq® taken?
Rinvoq® is a once-daily pill taken by mouth (orally). It is available for AD in 15 mg and 30 mg doses.
Who is Rinvoq® approved for?
Rinvoq® is approved for adults and children (12 years and older) with moderate to severe atopic dermatitis, who did not respond to other previous treatments and whose AD is not well controlled using other pills, injections (including biologics), or the use of other pills or injections is not recommended. Rinvoq® can be used with or without medicated topical therapies for atopic dermatitis.
What are the side effects of this medication?
All medications have risks and benefits, and the details of the risks and benefits should be reviewed with the prescribing health care professional. This medication may increase the risk of uncommon but serious events, such as blood clots, cardiac events, cancers, and certain infections. Oral JAK inhibitors also come with a black box warning (a ‘boxed’ or ‘black box’ warning can be found on prescription medications, depending on the side effects). If you or your child is experiencing this or has any concerns about the treatment, consult your prescribing health care professional.
What if my atopic dermatitis does not get better?
If you find your AD isn’t responding to treatment, let your doctor know, as your treatment plan may need to be adjusted. A qualified health care professional, such as a dermatologist, can help reassess your or your child’s condition and can potentially adjust the treatment plan. There is no cure for AD, but there are now many treatments that can help patients.
Eczema Society of Canada thanks Ashley Sutherland, MD, MSc, FRCPC, for her volunteer contribution to this educational content.
Reference: 1 AbbVie (April 2025). Rinvoq® (upadacitinib) [Product Monograph], extended-release tablets [oral use].
Disclaimer: Information provided in this resource does not constitute medical advice and is not intended to be used as a diagnostic tool. The information is up-to-date at the time of publication. All medications, interventions, and treatment plans have risks and benefits, and it is important that individuals discuss their or their child’s specific health care needs with a qualified health care professional.
